You would like to read
- Masala King Dr Dhananjay Datar inaugurates 50th Al Adil Super Store in Dubai
- UK - National Institute for Health and Care Excellence (NICE) issues MedTech Innovation Briefing on 'Trublood®- Prostate' for Non-invasive Cancer Diagnosis
- VABB - Advanced tissue sampling technique aiding in accurately diagnosing breast cancer and removal of smaller benign lumps
- Avon Reinforces Commitment to Creating Breast Cancer Awareness with Latest #InYourBreastInterest Campaign
- Masala King Dr Dhananjay Datar sponsors a novel initiative rickshaw ambulance for COVID patients in need of oxygen
Mumbai (Maharashtra) [India], November 20 (ANI/PRNewswire): Datar Cancer Genetics, a leading cancer research company today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Designation' for its blood test to detect early-stage Breast Cancer.
The blood test uses a proprietary technology developed by the company to detect Circulating Tumor Cells and Clusters specific to Breast Cancer with very high accuracy. Data from clinical trials has shown that the test can detect Stage 0 (DCIS) and Stage 1 Breast Cancers with accuracy of better than 99% without any false positives.
The test has been validated on more than 20,000 women comprising healthy and cancer patients. The test requires only 5 ml blood and does not involve exposure to any radiation or discomfort associated with mammography.
In India more than 1.7 lac women are detected with Breast Cancer, mostly at stage III or IV which makes the treatment toxic and expensive besides minimal chances of success. If detected early, Breast Cancer can be cured in almost 99% of the cases.
"This is for the first time that women above the age of 40 can obtain a Breast Cancer specific blood test in consultation with their physician from the convenience and privacy of their home or office. We are pleased with the recognition by the US FDA of our test as a breakthrough technology which is a momentous milestone. It underscores the potential of the test which we believe will revolutionize the early detection and cure of this dreaded disease worldwide. Moreover, it is a matter of great pride that our scientists and clinicians from India have put the country at the centre stage of global cancer research and this is an example of the Prime Minister's 'Atmanirbhar Bharat' mission," said Rajan Datar, Chairman of the Company.
The test is already available in Europe and is CE marked. The test will be available in India shortly as 'EasyCheck' and will be reasonably priced. The Company is in discussions with several leading healthcare providers for ready accessibility.
The Company has also validated a blood test to detect multiple cancers including several extremely lethal malignancies such as Lung, Pancreas and Ovaries and will be available next year.
This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)
DISCLAIMER
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
